Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) was the recipient of a large drop in short interest in May. As of May 31st, there was short interest totalling 26,678,100 shares, a drop of 28.3% from the May 15th total of 37,216,500 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is presently 38,111.6 days. Approximately 0.1% of the shares of the stock are sold short.

Sino Biopharmaceutical Trading Down 0.6%

SBMFF stock traded down $0.00 during midday trading on Thursday, reaching $0.64. The stock had a trading volume of 300 shares, compared to its average volume of 1,879. Sino Biopharmaceutical has a 52-week low of $0.31 and a 52-week high of $0.77. The company's fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.46.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.